Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial

Drug and Alcohol Dependence

Volumn 111, Issue 3, 2010, Pages 200-206

  Toll, Benjamin A ^a,b   White, Marney ^a   Wu, Ran ^a   Meandzija, Boris ^a   Jatlow, Peter ^a   Makuch, Robert ^a   O'Malley, S S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Naltrexone; Nicotine patch; Smoking cessation; Tobacco; Weight gain

Indexed keywords

DEPADE; NALTREXONE; NICOTINE; NICOTINE PATCH; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, CUTANEOUS; ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NICOTINE; PROSPECTIVE STUDIES; SMOKING; SMOKING CESSATION; WEIGHT GAIN;

NICOTIANA TABACUM;

EID: 77957323616     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.04.015     Document Type: Article

References (54)

1. Abelin T., Ehrsam R., Buhler-Reichert A., Imhof P., Muller P., Thommen A., Vesanen K. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find. Exp. Clin. Pharmacol. 1989, 11:205-214.
2. Ahluwalia J., Harris K., Catley D., Okuyemi K., Mayo M. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002, 288:468-474.
3. Ahmadi J., Ashkani H., Ahmadi M., Ahmadi N. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. J. Subst. Abuse Treat. 2003, 24:251-255.
4. Alsene K., Li Y., Chaverneff F., de Wit H. Role of abstinence and visual cues on food and smoking craving. Behav. Pharmacol. 2003, 14:145-151.
5. Babor T., de la Fuente J., Saunders J., Grant M. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care 1992, World Health Organization, Geneva, Switzerland.
6. Bodnar R., Hadjimarkou M., Krzanowska E., Silva R., Stein J. Differential dose-dependent effects of central morphine treatment upon food intake in male and female rats receiving neonatal hormone manipulations. Nutr. Neurosci. 2003, 6:53-57.
7. Bowen D., Spring B., Fox E. Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy. J. Behav. Med. 1991, 14:97-110.
8. Brown R., Burgess S., Sales S., Whiteley J., Evans D., Miller I. Reliability and validity of a smoking Timeline Followback interview. Psychol. Addict. Behav. 1988, 12:101-112.
9. Carroll M., France C., Meisch R. Food deprivation increases oral and intravenous drug intake in rats. Science 1979, 205:319-321.
10. Carroll M., Meisch R. Determinants of increased drug self-administration due to food deprivation. Psychopharmacology (Berl.) 1981, 74:197-200.
11. Cooper T., Klesges R., DeBon M., Zbikowski S., Johnson K., Clemens L. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addict. Behav. 2005, 30:61-75.
12. Copeland A., Brandon T., Tiffany S., Baker T. The Smoking Consequences Questionnaire - Adult: measurement of smoking outcome expectancies of experienced smokers. Psychol. Assess. 1995, 7:484-494.
13. Covey L., Glassman A., Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J. Addict. Dis. 1999, 18:31-40.
14. Cox L., Tiffany S., Christen A. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res. 2001, 3:7-16.
15. David S., Lancaster T., Stead L. Opiod antagonists for smoking cessation. Cochrane Database Syst. Rev. 2001, 3. Art No.: CD003086.
16. De La Garza R., Johanson C. The effects of food deprivation on the self-administration of psychoactive drugs. Drug Alcohol Depend. 1987, 19:17-27.
17. Doherty K., Militello F., Kinnunen T., Garvey A. Nicotine gum dose and weight gain after smoking cessation. J. Consult. Clin. Psychol. 1996, 64:799-807.
18. Fiore M., Jaén C., Baker T., Bailey W., Benowitz N., Curry S., et al. Treating Tobacco Use and Dependence 2008 Update: Clinical Practice Guideline 2008, USDHHS, Rockville, MD.
19. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders 1996, Biometrics Research, New York State Psychiatric Institute, New York. research version, patient edition.
20. Gonzales D., Rennard S., Nides M., Oncken C., Azoulay S., Billing C., Watsky E.J., Gong J., Reeves K.R. Varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47-55. Varenicline Phase 3 Study Group.
21. Hall S., Ginsberg D., Jones R. Smoking cessation and weight gain. J. Consult. Clin. Psychol. 1986, 54:342-346.
22. Hall S., Tunstall C., Vila K., Duffy J. Weight gain prevention and smoking cessation: cautionary findings. Am. J. Public Health 1992, 82:799-803.
23. Heatherton T., Kozlowski L., Frecker R., Fagerström K. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br. J. Addict. 1991, 86:1119-1127.
24. Hudmon K., Gritz E., Clayton S., Nisenbaum R. Eating orientation, postcessation weight gain, and continued abstinence among female smokers receiving an unsolicited smoking cessation intervention. Health Psychol. 1999, 18:29-36.
25. Hughes J. Tobacco withdrawal in self-quitters. J. Consult. Clin. Psychol. 1992, 60:689-697.
26. Hurt R., Sachs D., Glover E., Offord K., Johnston J., Dale L., Khayrallah M., Schroeder D., Glover P., Sullivan C., Croghan I., Sullivan P. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 1997, 337.
27. Jorenby D., Hays J., Rigotti N., Azoulay S., Watsky E., Williams K., Billing C.B., Gong J., Reeves K.R. Efficacy of varenicline, an alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296:56-63. Varenicline Phase 3 Study Group.
28. Jorenby D., Leischow S., Nides M., Rennard S., Johnston J., Hughes A., Smith S., Muramoto M., Daughton D., Doan K., Fiore M., Baker T. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999, 340:685-691.
29. King A., de Wit H., Riley R., Cao D., Niaura R., Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob. Res. 2006, 8:671-682.
30. Klesges R., Winders S., Meyers A., Eck L., Ward K., Hultquist C., Ray J., Shadish W. How much weight gain occurs following smoking cessation: a comparison of weight gain using both continuous and point prevalence abstinence. J. Consult. Clin. Psychol. 1997, 65:286-291.
31. Krishnan-Sarin S., Meandzija B., O'Malley S. Naltrexone and nicotine patch in smoking cessation: a preliminary study. Nicotine Tob. Res. 2003, 5:851-857.
32. Lang W., Latiff A., McQueen A., Singer G. Self administration of nicotine with and without a food delivery schedule. Pharmacol. Biochem. Behav. 1977, 7:65-70.
33. Leeman R., McKee S., Toll B., Krishnan-Sarin S., Cooney J., Makuch R., O'Malley S. Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine Tob. Res. 2008, 10:1793-1809.
34. O'Malley S., Cooney J., Krishnan-Sarin S., Dubin J., McKee S., Cooney N., Blakeslee A., Meandzija B., Romano-Dahlgard D., Wu R., Makuch R., Jatlow P. Controlled trial of naltrexone augmentation of nicotine replacement for smoking cessation. Arch. Intern. Med. 2006, 166:667-674.
35. O'Malley S., Krishnan-Sarin S., McKee S., Leeman R., Cooney N., Meandzija B., Wu R., Makuch R. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. Int. J. Neuropharmacol. 2009, 12:589-597.
36. Parsons A., Shraim M., Inglis J., Aveyard P., Hajek P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst. Rev. 2009, 1. Art No.: CD006219.
37. Perkins K., Marcus M., Levine M., D'Amico D., Miller A., Broge M., Ashcom J., Shiffman S. Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J. Consult. Clin. Psychol. 2001, 69:604-613.
38. Pettinati H., O'Brien C., Rabinowitz A., Wortman S., Oslin D., Kampman K.M., Dackis C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006, 26:610-625.
39. Pirie P., McBride C., Hellerstedt W., Jeffery R., Hatsukami D., Allen S., Lando H. Smoking cessation in women concerned about weight. Am. J. Public Health 1992, 82:1238-1243.
40. Pomerleau C., Zucker A., Stewart A. Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers. Nicotine Tob. Res. 2001, 3:51-60.
41. Rose J., Levin E., Behm F., Adivi C., Schur C. Transdermal nicotine facilitates smoking cessation. Clin. Pharmacol. Ther. 1990, 47:323-330.
42. Silagy C., Lancaster T., Stead L., Mant D., Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2004, (3). p. Art. No.: CD000146.pub000142.
43. Sobell L., Sobell M. Alcohol consumption measures. Assessing Alcohol Problems: A Guide for Clinicians and Researchers 2003, 75-99. National Institute on Alcohol Abuse & Alcoholism, Bethesda, MD. second edition. J. Allen, V. Wilson (Eds.).
44. Swan G.E., McAfee T., Curry S.J., Jack L.M., Javitz H., Dacey S., Bergman K. Effectiveness of bupropion sustained release for smoking cessation in a health care setting. Arch. Intern. Med. 2003, 163:2337-2344.
45. Tabarin A., Diz-Chaves Y., Carmona, Mdel C., Catargi B., Zorrilla E.P., Roberts A., Coscina D.V., Rousset S., Redonnet A., Parker G.C., Inoue K., Ricquier D., Pénicaud L., Kieffer B.L., Koob G.F. Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a "thrifty gene" Diabetes 2005, 54:3510-3516.
46. Toll B., Leary V., Wu R., Salovey P., Meandzija B., O'Malley S. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict. Behav. 2008, 33:173-179.
47. Toll B., O'Malley S., McKee S., Salovey P., Krishnan-Sarin S. Confirmatory factor analysis of the Minnesota Nicotine Withdrawal Scale. Psychol. Addict. Behav. 2007, 21:216-225.
48. Tønnesen P., Tonstad S., Hjalmarson A., Lebargy F., Van Spiegel P., Hider A., Sweet R., Townsend J. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J. Intern. Med. 2003, 254:184-192.
49. West R., Courts S., Beharry S., May S., Hajek P. Acute effect of glucose tablets on desire to smoke. Psychopharmacology 1999, 147:319-321.
50. West R., Hajek P., Burrows S. Effect of glucose tablets on craving for cigarettes. Psychopharmacology 1990, 101:555-559.
51. West R., Willis N. Double-blind placebo controlled trial of dextrose tablets and nicotine patch in smoking cessation. Psychopharmacology 1998, 136:201-204.
52. White M., Grilo C., O'Malley S., Potenza M. Binge eating disorder, obesity, and tobacco smoking. J. Addict. Med. 2010, 4:11-19.
53. Wilcox C., Oskooilar N., Erickson J., Billes S., Katz B., Tollefson G., Dunayevich E. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict. Behav. 2010, 35:229-234.
54. Wong G., Wolter T., Croghan G., Croghan I., Offord K., Hurt R. A randomized trial of naltrexone for smoking cessation. Addiction 1999, 94:1227-1237.